-
Coghill, DR, Banaschewski, T, Lecendreux, M, Zuddas, A, Dittmann, RW, Otero, IH, Civil, R, Bloomfield, R, Squires, LA.
Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial.
European Child & Adolescent Psychiatry
23(2)
:
61 -68
2014
view publication
-
Dittmann, RW, Cardo, E, Coghill, DR, Nagy, P, Anderson, CS, Adeyi, B, Caballero, B, Hodgkins, P, Civil, R.
EPA-0775 – Efficacy of lisdexamfetamine dimesylate and atomoxetine in child and adolescent subgroups from a head-tohead, double-blind, randomized trial in patients with attention-deficit/hyperactivity disorder.
European Psychiatry
29:
1
2014
view publication
-
Soutullo, C, Banaschewski, T, Lecendreux, M, Johnson, M, Zuddas, A, Hodgkins, P, Adeyi, B, Squires, LA, Coghill, DR.
EPA-0994 – Assessing adhd stimulant treatment efficacy using the weiss functional impairment rating scale: strengths and weaknesses.
European Psychiatry
29:
1
2014
view publication
-
Banaschewski, T, Lecendreux, M, Soutullo, C, Zuddas, A, Sorooshian, S, Adeyi, B, Squires, LA, Civil, R, Coghill, DR.
EPA-0719 – Post hoc analyses on the efficacy of lisdexamfetamine dimesylate following previous treatment with attention deficit/hyperactivity disorder medication.
European Psychiatry
29:
1
2014
view publication
-
Hodgkins, P, Setyawan, J, Banaschewski, T, Soutullo, C, Lecendreux, M, Johnson, M, Zuddas, A, Adeyi, B, Squires, LA, Coghill, DR.
EPA-0993 – Health utility scores in children and adolescents with attention-deficit/hyperactivity disorder: response to stimulant treatment.
European Psychiatry
29:
1
2014
view publication